mRNA drug offers hope for treating a devastating childhood disease
Drug trial results show that vaccines aren’t the only use for the mRNA technology behind the most widely used COVID-19 jabs....
03 April, 2024
Author: UW CTI
Long COVID still has no cure — so these patients are turning to research
With key long COVID trials yet to yield results, people with the condition are trying to change how clinical trials are done....
02 April, 2024
Will NIH & Industry Consider Universal Coronavirus Vax Developed by Scientists in Georgia/Wisconsin & Tokyo?
Georgia Institute of Technology Scientists, in collaboration with investigators from University of Wisconsin—Madison as well as University of Tokyo continued pursuing the optimal coronavirus vaccine since the Covid-19 pandemic started....
02 April, 2024
How Wisconsin Has Become a Rising Biohealth Powerhouse and Startup Haven
From networking, to funding, to hiring top talent and everything in-between, an increasing number of biohealth startups are calling the Badger State home....
01 April, 2024
How History Has Shaped Racial and Ethnic Health Disparities
This timeline offers a historical view of significant U.S. federal policies and events spanning the early 1800s to today that have influenced present-day health disparities....
29 March, 2024
Video: Cancer-busting vaccines
Treatments that could train the immune system to identify and destroy cancer cells are on the way....
27 March, 2024
UW unveils intellectual property models to build industry partnerships
From new options for cancer diagnosis and treatment, to improved wireless communications, researchers at the University of Wisconsin–Madison are developing game-changing innovations for the marketplace with the support of industry partners....
26 March, 2024
New federal spending bills to boost UW–Madison research initiatives
The University of Wisconsin–Madison is set to receive more than $56 million in new funding for research initiatives after the passage of two federal appropriations packages....
26 March, 2024
FDA Nod in Duchenne Helps Wider Swath of Patients With the Rare Muscle Disease
Corticosteroids are a standard first-line treatment for Duchenne muscular dystrophy, but these drugs have many side effects. FDA approval of Italfarmaco’s Duvyzat is the first nonsteroidal drug to pass the agency’s regulatory bar for treating this rare disease....
22 March, 2024
How Equity and Inclusion Drive True Diversity in Clinical Research
Moultrie explains that “people from marginalized populations must be fully welcome and treated equitably, sharing the same experience as earlier participants in all these discussions. This includes having updates on earlier conversations to enable full participation in current discussions....
14 March, 2024